178 related articles for article (PubMed ID: 35295488)
1. Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome.
Boonma P; Shapiro JM; Hollister EB; Badu S; Wu Q; Weidler EM; Abraham BP; Devaraj S; Luna RA; Versalovic J; Heitkemper MM; Savidge TC; Shulman RJ
Front Pain Res (Lausanne); 2021; 2():691689. PubMed ID: 35295488
[No Abstract] [Full Text] [Related]
2. Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial.
Ankersen DV; Weimers P; Bennedsen M; Haaber AB; Fjordside EL; Beber ME; Lieven C; Saboori S; Vad N; Rannem T; Marker D; Paridaens K; Frahm S; Jensen L; Rosager Hansen M; Burisch J; Munkholm P
J Med Internet Res; 2021 Dec; 23(12):e30291. PubMed ID: 34904950
[TBL] [Abstract][Full Text] [Related]
3. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study.
Wong RK; Yang C; Song GH; Wong J; Ho KY
Dig Dis Sci; 2015 Jan; 60(1):186-94. PubMed ID: 25092036
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.
Kim HJ; Camilleri M; McKinzie S; Lempke MB; Burton DD; Thomforde GM; Zinsmeister AR
Aliment Pharmacol Ther; 2003 Apr; 17(7):895-904. PubMed ID: 12656692
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.
Kim HJ; Vazquez Roque MI; Camilleri M; Stephens D; Burton DD; Baxter K; Thomforde G; Zinsmeister AR
Neurogastroenterol Motil; 2005 Oct; 17(5):687-96. PubMed ID: 16185307
[TBL] [Abstract][Full Text] [Related]
6. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P
Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426
[TBL] [Abstract][Full Text] [Related]
7. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
[TBL] [Abstract][Full Text] [Related]
8. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.
Skrzydło-Radomańska B; Prozorow-Król B; Cichoż-Lach H; Majsiak E; Bierła JB; Kanarek E; Sowińska A; Cukrowska B
Nutrients; 2021 Feb; 13(3):. PubMed ID: 33652763
[TBL] [Abstract][Full Text] [Related]
9. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial.
Bogovič Matijašić B; Obermajer T; Lipoglavšek L; Sernel T; Locatelli I; Kos M; Šmid A; Rogelj I
J Dairy Sci; 2016 Jul; 99(7):5008-5021. PubMed ID: 27157575
[TBL] [Abstract][Full Text] [Related]
10. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial.
Shin SY; Park S; Moon JM; Kim K; Kim JW; Chun J; Lee TH; Choi CH;
J Neurogastroenterol Motil; 2022 Oct; 28(4):642-654. PubMed ID: 36250371
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome.
Michail S; Kenche H
Probiotics Antimicrob Proteins; 2011 Mar; 3(1):1-7. PubMed ID: 22247743
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome.
Connell M; Shin A; James-Stevenson T; Xu H; Imperiale TF; Herron J
Neurogastroenterol Motil; 2018 Dec; 30(12):e13427. PubMed ID: 30069978
[TBL] [Abstract][Full Text] [Related]
13. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.
Staudacher HM; Lomer MCE; Farquharson FM; Louis P; Fava F; Franciosi E; Scholz M; Tuohy KM; Lindsay JO; Irving PM; Whelan K
Gastroenterology; 2017 Oct; 153(4):936-947. PubMed ID: 28625832
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome.
Xu H; Ma C; Zhao F; Chen P; Liu Y; Sun Z; Cui L; Kwok LY; Zhang H
Eur J Nutr; 2021 Aug; 60(5):2553-2565. PubMed ID: 33225399
[TBL] [Abstract][Full Text] [Related]
15. Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study.
Marchix J; Quénéhervé L; Bordron P; Aubert P; Durand T; Oullier T; Blondeau C; Ait Abdellah S; Bruley des Varannes S; Chaffron S; Coron E; Neunlist M
Microorganisms; 2023 Jan; 11(2):. PubMed ID: 36838241
[TBL] [Abstract][Full Text] [Related]
16. Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome.
Distrutti E; Cipriani S; Mencarelli A; Renga B; Fiorucci S
PLoS One; 2013; 8(5):e63893. PubMed ID: 23691109
[TBL] [Abstract][Full Text] [Related]
17. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
[TBL] [Abstract][Full Text] [Related]
18. Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function.
Dai C; Guandalini S; Zhao DH; Jiang M
Mol Cell Biochem; 2012 Mar; 362(1-2):43-53. PubMed ID: 22020749
[TBL] [Abstract][Full Text] [Related]
19. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
Ishaque SM; Khosruzzaman SM; Ahmed DS; Sah MP
BMC Gastroenterol; 2018 May; 18(1):71. PubMed ID: 29801486
[TBL] [Abstract][Full Text] [Related]
20. Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation.
Kim SE; Choi SC; Park KS; Park MI; Shin JE; Lee TH; Jung KW; Koo HS; Myung SJ;
J Neurogastroenterol Motil; 2015 Jan; 21(1):111-20. PubMed ID: 25537674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
